CMOPF Cosmo Pharmaceuticals NV Forecast, Technical & Fundamental Analysis

Momentum Indicator for CMOPF turns positive, indicating new upward trend

CMOPF saw its Momentum Indicator move above the 0 level on December 23, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator turned positive. In of the 22 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CMOPF just turned positive on December 03, 2025. Looking at past instances where CMOPF's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .

CMOPF moved above its 50-day moving average on December 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CMOPF crossed bullishly above the 50-day moving average on December 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Aroon Indicator for CMOPF entered a downward trend on December 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.920) is normal, around the industry mean (9.054). P/E Ratio (31.715) is within average values for comparable stocks, (24.434). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.056). Dividend Yield (0.018) settles around the average of (0.026) among similar stocks. CMOPF's P/S Ratio (10.152) is slightly higher than the industry average of (3.759).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMOPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.